Celtic Therapeutics Rebrands as Auven Therapeutics

 

US VIRGIN ISLANDS, Caribbean & NEW YORK & LAUSANNE, Switzerland--(Business
Wire)--
Celtic Therapeutics Management L.L.L.P. (Celtic Therapeutics), the global
private equity company focused on acquiring novel, life-saving and quality of
life-enhancing products and accelerating the development of these products, has
announced a name change to Auven Therapeutics Management L.L.L.P (Auven
Therapeutics) effective from March 11, 2013. The name change was made in order
to overcome confusion related to other Celtic entities, which are not part of
Auven Therapeutics. 

Auven Therapeutics` rebrand reflects the Company`s mission to provide the gold
(Au) standard in drug (Ven) development, progressing promising therapeutic
pharmaceutical candidates in areas of unmet medical need. 

Auven Therapeutics was founded by Dr. Peter B. Corr and Stephen Evans-Freke in
2007 and is pursuing an innovative investment strategy - while it is structured
as a private equity fund, it also operates as a drug development company. 

Commenting on the new name and the strategy of the fund, co-founder and
co-Managing General Partner Stephen Evans-Freke said: 

"Capitalizing on the wealth of expertise of our development team, we take
ownership and control of the development of carefully selected clinical-stage
therapeutic assets in order to build value around them to the point where they
are attractive acquisition opportunities for established pharmaceutical and
biotechnology companies." 

Auven Therapeutics has a portfolio of biologic and small molecule therapeutic
candidates, primarily comprising preclinical to mid-stage development programs,
for a wide range of therapeutic indications including cancer, ophthalmic
conditions, women`s health and orphan diseases. It has ownership of or a
majority interest in the therapeutic assets of ADC Therapeutics, Spirogen,
Resolvyx and Kiacta, and a minority investment in Kolltan and Sprout
Pharmaceuticals. 

Dr. Peter B. Corr, co-founder and co-Managing General Partner added: 

"We are excited about our portfolio of innovative therapeutic assets. In
particular, our investments in Spirogen and ADC Therapeutics have great
potential to develop new and much more effective treatments for a variety of
cancers." 

For more information, visit the new Auven Therapeutics` website at
www.auventx.com

Ends 

Notes to Editors

About Auven Therapeutics

Auven Therapeutics Management L.L.L.P. (previously known as Celtic Therapeutics
Management L.L.L.P.) is an investment advisor with its principal place of
business in the US Virgin Islands. It manages Auven Therapeutics Holdings L.P.
(previously known as Celtic Therapeutics Holdings L.P.), a private equity fund,
which has its registered office and principal place of business in the British
Virgin Islands. Stephen Evans-Freke and Dr. Peter B. Corr are the Managing
General Partners of Auven Therapeutics Management L.L.L.P., and the other
Managing Directors of the firm are Reinaldo Diaz and Beth Hecht (New York),
Michael Forer (Lausanne) and Dr. Richard Warburg (USVI)). Auven Therapeutics
Development (previously known as Celtic Therapeutics Development), is the
operating company of Auven Therapeutics Holdings L.P. and manages drug
development from its bases in Lausanne, Switzerland, New York, USA and Hamilton,
Bermuda.

At Auven Therapeutics:
Investor Relations
Kathy Armstrong:
T: +1-(212)-616-4042
[email protected]
or
Media enquiries:
College Hill Life Sciences
Sue Charles/Stefanie Bacher/Gemma Howe
T: +44-(0)20-7866-7866
[email protected]

Copyright Business Wire 2013

Suggested Articles

Boehringer Ingelheim is licensing an autotaxin inhibitor from Bridge Biotherapeutics for €45 million and promising more than €1 billion in biobucks.

In this week's EuroBiotech Report, Gilead and Galapagos ink big deal, Novartis chalks up Alzheimer’s failure and AM-Pharma raises €116 million.

In our EuroBiotech roundup this week, Oryzon posts phase 2 Alzheimer’s data, Mereo eyes fast approval and AC Immune advances Lilly-partnered drug.